

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/21761> holds various files of this Leiden University dissertation.

Author: Hurk, Corina van den

Title: Safety and effectiveness of scalp cooling in cancer patients undergoing cytotoxic treatment

Issue Date: 2013-09-19

Chapter 4



Scalp cooling to prevent alopecia after chemotherapy can be considered safe in patients with breast cancer

C.J.G. van den Hurk, L.V. van de Poll-Franse, W.P.M. Breed,
J.W.W. Coebergh, J.W.R. Nortier

Breast. 2013; in press

Abstract

With modern scalp cooling equipment cytotoxic damage of hair root cells can be prevented in half of the patients with cancer at high risk of alopecia. However, traditionally doubt has existed whether scalp cooling might facilitate hiding and disseminating scalp skin metastases and thus decrease survival. We discuss this risk using frequency data on metastases in breast cancer from observational and autopsy studies and the Munich Cancer Registry. They showed the incidence of scalp skin metastases to be very low and not differ between scalp-cooled (0.04-1%) and non scalp-cooled (0.03-3%) patients with breast cancer and in need of chemotherapy. We found it rather unlikely that the incidence of scalp skin metastases might increase at all after scalp cooling, whereas a very small proportion of patients receiving chemotherapy are at risk to develop metastases at this site. Scalp cooling can thus safely be offered to patients treated with alopecia-inducing chemotherapy.

Viewpoints and debates

Scalp cooling probably diminishes the cytotoxic damage of hair root cells through vasoconstriction and a reduced biochemical activity of the cytotoxic agents and their metabolites.¹ It is mainly used in Western Europe by breast cancer patients and prevents severe chemotherapy-induced alopecia (CIA) in half of them.² Scalp cooling is usually applied continuously about 30 minutes before, until 90 minutes after chemotherapy infusion¹, lowering scalp skin temperature to a mean of 18°C (range 12-25°C) (unpublished results). But can hypothermia by scalp cooling also promote outgrowth of scalp skin metastases?

This risk is particularly important for patients without metastases at primary diagnosis (M0), as in metastatic disease (M1) a scalp skin metastasis will rarely be unique, nor lethal. If after adjuvant chemotherapy scalp skin metastases would occur more frequently with than without scalp cooling, this supportive care modality might affect that risk. We now discuss the incidence of (scalp) skin metastases in different groups of breast cancer patients according to treatment with chemotherapy and/ or scalp cooling.

Incidence of scalp skin metastases in non scalp-cooled breast cancer patients

Without scalp cooling the incidence of *skin metastases* in patients with breast cancer varied between 2-30% in retrospective patient file studies³⁻⁵ and 3% in a German cancer registry (Table 1).⁶ In addition, it varied between 9-32% in autopsy studies before chemotherapy was used.⁷⁻¹⁰ These broad ranges may be caused by the distinction between true distant metastasis and local chest wall involvement, selection of microscopically confirmed metastases or maybe differences in incidence determined by race.⁴ Skin metastases are rarely the first presenting sign of distant metastatic breast cancer¹¹⁻¹⁵, also when patients did not undergo systemic treatment after primary local treatment.¹⁶ The majority (53-84%) of skin metastases is detected on the trunk or near the scar of the primary neoplasm.^{3, 12, 15, 17, 18}

The incidence of skin metastases alone has been studied among 33,771 M0 breast cancer patients in the Munich Cancer Registry (MCR) in the periods 1978-84, 1985-94 and 1994-2003.⁶ Combining all periods, skin metastases were prevalent in 929 (3%) patients and skin metastases alone in 191 (0.6%) patients. In this last group, 27% of the patients had received adjuvant chemotherapy as initial treatment. Skin metastases alone became prevalent later in follow-up than other single sites or combinations of metastases.⁶ In 20% of these patients they were diagnosed >10 years after initial diagnosis. The sub-site of skin metastases alone as well type of systemic treatment after metastases were unknown.

Active follow-up of the frequency of *scalp skin metastases* in breast cancer patients without scalp cooling showed the incidence to vary between 0.03-3%^{3, 11, 12, 19-22}, remaining low in a study population of high risk patients only²⁰, even in M1 patients^{3, 11, 12} or when the study was prospective.¹⁹ Incidence rates were not associated with time since diagnosis (110 months)²⁰ or receiving no adjuvant chemotherapy.¹² One study showed that also scalp skin metastases occurred at the same time or later than non-skin metastases elsewhere.²⁰

Incidence of scalp skin metastases in scalp-cooled breast cancer patients that were systematically followed

Active follow-up of the frequency of *scalp skin metastases* in scalp-cooled breast cancer patients showed an incidence below 1.1% (Table 2).^{19, 22, 28} Lemieux et al. described at a follow-up of 5.8 years six patients (1.1%) with stage II and III breast cancer (n=553) who had developed scalp skin metastases, but never as an isolated site of relapse.²² Besides, two breast cancer patients were reported in whom seven and nine years after diagnosis scalp skin metastases were detected as first metastatic site,²⁸ but scalp cooling most likely had not affected the prognosis unfavourably; The first patient only had used scalp cooling for two out of four cycles and lost her hair. A few months after detection of the scalp skin metastases many other metastases were found. The second patient used scalp cooling during one out of six cycles of chemotherapy. Six years later she received another six cycles without scalp cooling and two years later the scalp skin metastases were diagnosed.

Incidence of scalp skin metastases in scalp-cooled breast cancer patients that were not systematically followed

Literature research of the frequency of *scalp skin metastases* in scalp-cooled patients (n=2315), at least 49% with breast cancer, led to 38 original articles carried out during 1970 to 2012^{1, 29}, and four additional studies (Table 2).³⁰⁻³³ At least 37% of these patients had received adjuvant chemotherapy. These studies never assessed scalp skin metastases systematically and follow-up was mostly short (2-46 months) or unknown (n=30). Overall 17 studies addressed scalp skin metastases, which were detected in nine patients (0.4%). Seven of these patients had advanced disease and scalp skin metastases were never the first and only site of relapse. For two patients the course of disease was unknown.²⁶

Data of >2000 Dutch scalp-cooled patients have been analysed in our studies from 2004 to 2012.^{2, 34-37} Of >1800 (87%) female breast cancer patients 77% were treated in the adjuvant setting, mainly with anthracyclines or taxanes. In one patient, a scalp skin metastasis had been spontaneously reported, after the first treatment cycle with docetaxel monotherapy for liver metastases and previous chemo- and hormonal therapy. However, scalp skin metastases were not systematically assessed.

Discussion

This overview shows that the incidence of scalp skin metastases in breast cancer patients seems to be comparable for scalp-cooled (0.04-1%) and for non scalp-cooled patients (0.03-3%). Despite the high vascularisation and immobile environment of the scalp skin³⁸, the low incidence indicates that it is not a site where metastases seed easily. The limited occurrence probably cannot be attributed to the effectiveness of chemotherapy. Firstly, because the incidence of (*scalp*) *skin metastases* was also low when chemotherapy was not yet available.^{7-10, 12} Secondly, the MCR exhibited the proportion of *skin metastases* not to differ in the periods 1978-84, 1985-94 and 1994-2003, despite changes in systemic treatment and stage distribution.⁶ This would indicate that scalp cooling does not pose a risk for development of scalp skin metastases.

Of all patients receiving chemotherapy, only patients who have proliferating micro-metastases in the scalp skin, which survive despite chemotherapy, are at risk for scalp skin metastases due to scalp cooling. If metastases develop as a result of primary resistance for chemotherapy⁴⁰, or in case of late relapses from micro-metastases in a dormant state for many years after cytotoxic treatment^{41, 42}, scalp cooling cannot cause any additional harm. However, as long as the risk of scalp skin metastases before and after adjuvant systemic therapy cannot be predicted accurately, the potential -but likely low- harmful effect of scalp cooling for an individual patient remains unknown and needs to be acknowledged.

Scalp skin metastases are usually detected later than or concurrent with metastases at other sites, possibly due to intrinsic mechanisms that initiate late relapses of dormant cells.³⁹ ⁴¹ Cutaneous metastases might thus often be an indication for other distant metastases elsewhere in the body.⁴³

During scalp cooling cytotoxics do reach the *scalp skin*, but with a decrease of scalp skin perfusion of approximately 20% at a local temperature of around 20°C.²³ After chemotherapy infusion the concentration of the cytotoxic agents and its metabolites decreases gradually, remaining there when scalp cooling is ceased. Thus, hair follicle cells of scalp-cooled patients are probably damaged, but able to recover. Therefore, hair production is temporarily diminished, resulting in a small constricted section of the hair.²⁴ And indeed, mostly there is some additional hair loss in the period between chemotherapy cycles.²⁵ Furthermore, two studies reported independently that pre-existing scalp skin metastases regressed during chemotherapy despite scalp cooling.^{26, 27} One patient preserved the hair, while the other lost it.

Should the low risk for scalp skin metastases be taken for granted from the existing medical literature? Firstly, the follow-up of most studies is short. However, the first peak of relapses in breast cancer occurs one to two years after clinical diagnosis.^{41, 44} Nevertheless, scalp cooling might change the time to the emergence of scalp skin metastasis. Secondly, it is likely that the incidence of scalp skin metastases has been underreported, as the patient is often asymptomatic and physical examination of the scalp is on demand only, on the patients indication.^{13, 18} Thirdly, it seems rather complicated to measure micro-metastases in the highly vascularised scalp skin.

Although medical professionals may be more alert of scalp skin metastases in a scalp-cooled patient, they might still be overlooked because of their low incidence, (concurrent) skin metastases at other sites or other life threatening metastases elsewhere that kill the patient probably before the detection of a scalp skin metastasis. The true proportion of these patients is unknown, also because in autopsy studies the skin is often excluded.⁴⁵ But this also indicates that these metastases are mostly not clinically important.²²

In conclusion, in patients with solid tumours, an unfavourable development of the disease due to scalp cooling has never been documented. It is therefore unlikely that the local efficacy of chemotherapy is decreased to such an extent, that the extremely low baseline risk increases. It is never a reason to omit scalp cooling with palliative treatment, which also

seems safe for the adjuvant chemotherapy setting. Most Dutch medical oncologists currently consider the risk so low that they provide scalp cooling in the adjuvant setting in 80% of the >70 Dutch scalp cooling hospitals. Remaining doubts might be addressed by studying a large cohort of scalp-cooled patients³⁶ using a cancer registry and prospectively compare survival between scalp-cooled and non scalp-cooled patients.

Table 1. Overview of studies of skin and scalp skin metastases in patients with breast cancer without scalp cooling.

Study	n=	Skin mets		Scalp skin		Syst	Duration of		Chemo (%) /		Type ^a	Remarks
		(%)	(?) ^c	mets (%)	mets (<3)		Follow up	Adj (%)	0			
Brownstein 1972 ²⁰	NR ^b	168	(?) ^c	5	(<3)	Yes	NR	(included in 1948-1963)	0			^b % M1 ^a unknown
Fisher 1982 ²¹	7800	NR		2 ^d	(0.03)	Yes	NR		?/100	?		^c 100% biopsy proven
Lookingbill 1990 ²² /1993 ²³	992 ^{e,f}	71 ^g	(7)	18	(2)	Yes	NR	(included in 1976-1986)	?/?	?		^d first occurrence ^e distant (n=20) or distant combined with local (n=51) metastasis
Spaeth 2008 (abstract) ²	141 ^{h,j}	NR		(<3) ⁱ		Yes	Median 3 yrs		100/?		Anthraand/ or taxanes	^f % M1 unknown ^g 79% biopsy proven ^h 93% breast ca ⁱ % M1 unknown ^j includes also skull and brain metastases
Lemieux 2009 ²⁴	87	M0	NR	1 ^k	(1)	Yes	Median 5.4 yrs		100/100		Anthra/ CMF/ taxanes	^k no scalp cooling during adjuvant treatment, developing scalp skin metastasis after 6 out of 9 systemic treatments for metastatic disease with scalp cooling

table 1. continues on next page

Van de Sande 2010 ²⁵	885 M0 ^l	25 (3)	4 ^m (0.5)	Yes	Mean 9.2 yrs	100/100	FEC/ FEC+CTC	^l high risk: 4+ lymph nodes ^m Scalp skin concurrent with other sites ⁿ scalp skin <u>alone</u>
MCR 2011	33.771 M0	929 (3)/ 191 (0.6) skin alone	(<0.6) ⁿ	No	Mean 8.2 yrs	29/100	NR	

Syst= (scalp) skin metastases systematically studied, Pt=patient, Chem= chemotherapy, Adj=adjuvant chemotherapy, Type= type of chemotherapy, NR= not reported, yrs=years, M0= without metastases at diagnosis, M1=metastasised disease at diagnosis

^a Anthra= anthracyclines, CMF= Cyclophosphamide, Methotrexate, 5-Fluorouracil, FEC=5-Fluorouracil, Epirubicin, Cyclophosphamide, CTC= Cyclophosphamide, Thiotepa, Carboplatin



Table 2. Overview of studies of scalp skin metastases in scalp-cooled patients with (mainly) breast cancer.

Study	n=	Scalp skin			Follow up	Adj (%)	Type ^a	Remarks
		nets (%)	Syst	mets (%)				
Van den Hurk (1997-2005)	390	3 (0.8) ^b	Yes	Median 2.2 y	NR	Anthra/ taxane/ CMF	^b 1x before start chemotherapy, 2x following metastases at other sites	
Spaeth 2008 (abstract) ²	770 ^c	3 (0.04) ^d	Yes	Median 3 y	NR	Anthra and/or taxane	^c 93% breast ca ^d personal communication	
Lemieux 2009 ²⁴	553	6 (1.1) ^e	Yes	Median 5.8 y	100	Anthra/ CMF/ taxane	^e not first metastatic site	
Lemieux 2011 ²⁶	2	2 ^f	Yes	7+9 y	100		^f first and only site, stop scalp cooling after 1 or 2 cycles	
Van den Hurk (2004-12) ^{4,27-30}	>2000 ^g	1 (0.04) ^h	No	n.a.	77	Diverse	^g 87% breast ca ^h detected after first chemotherapy	
Literature (1970-2013)	2315 ⁱ	9 (0.4)	No	n.a.	>439 (37)	Diverse	ⁱ at least 1287 (49%) breast ca	
No mets info ⁿ	1204 ^j	NR	No	n.a.	>237 (46)	Diverse	^j at least 511 (42%) breast ca	
No mets -FU ^o	268 ^k	0	No	NR	NR	Diverse	^k at least 190 (71%) breast ca	
No mets +FU ^p	309 ^l	0	No	9-46 m	133 (58)	Diverse	^l 74% breast ca	
Mets ^q	307 ^m	9	No	2-20 m	NR	Diverse	^m at least 131 (43%) breast ca	

Syst= scalp skin metastases systematically studied, Adj=adjuvant chemotherapy, Type= type of chemotherapy, NR= not reported, y=years, m= months, n.a. not applicable, mets=metastases, FU=follow-up

^a Anthra= anthracyclines, CMF= Cyclophosphamide, Methotrexate, 5-Fluorouracil

ⁿ No information about scalp skin metastases, references: Adams 1992, Anderson 1981, Auvinen 2010, Belpomme 1982, Benglia 1986, Ciambellotti 1993, David 1987, Dean 1983, Dougherty 1996, Goldhirsch 1982, Gregory 1982, Hunt 1982, Kargar 2011, Keizer-Heldens 2009, Kennedy 1983, Kolen 2002, Nakazawa 1985, Robinson 1987, Samonigg 1984, Symonds 1986, Tierney 1992

^o No scalp skin metastases, follow up unknown, references: Giaccone 1988, Hillen 1990, Katsimbri 2000, Macduff 2003, Massey 2004, Satterwhite 1984

^p No scalp skin metastases, follow up known, references: Lemenager 1997, Parker 1987, Protiere 2002, Ridderheim 2003, Ron 1997, Tollenaar 1994

^q Scalp skin metastases, references: Christoudoulou 2006, Kiser 1982, Middleton 1985, Peck 2000, Vendelbo-Johansen 1985

Literature

1. Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. *Ann Oncol* 2005;16:352-58.
2. Hurk van den CJG, Peerbooms M, Komen M, Nortier JWR, Smorenburg CH, Breed WPM. Multicenter results of scalp cooling to prevent chemotherapy-induced alopecia in 1500 breast cancer patients. *Suppl to Cancer Res* 2011;71:1s-653s Page 594s.
3. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. *J Am Acad Dermatol* 1993;29:228-36.
4. Hu SC, Chen GS, Wu CS, Chai CY, Chen WT, Lan CC. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. *J Am Acad Dermatol* 2009;60:379-87.
5. Manders K, van de Poll-Franse LV, Creemers GJ, et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. *BMC Cancer* 2006;6:179.
6. Hurk van den CJ, Eckel R, Poll van de-Franse LV, et al. Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry. *Breast Cancer Res Treat* 2011;128:795-805.
7. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. *Cancer* 1950;3:74-85.
8. Spencer PS, Helm TN. Skin metastases in cancer patients. *Cutis* 1987;39:119-21.
9. Enticknap JB. An analysis of 1,000 cases of cancer with special reference to metastasis. *Guys Hosp Rep* 1952;101:273-9.
10. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. *J Surg Oncol* 1983;23:175-80.
11. Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of internal carcinoma. A retrospective study of 7316 cancer patients. *J Am Acad Dermatol* 1990;22:19-26.
12. Brownstein MH, Helwig EB. Metastatic tumors of the skin. *Cancer* 1972;29:1298-307.
13. Schwartz RA. Cutaneous metastatic disease. *J Am Acad Dermatol* 1995;33:161-82; quiz 183-6.
14. Carson HJ, Pelletiere EV, Lack E. Alopecia neoplastica simulating alopecia areata and antedating the detection of primary breast carcinoma. *J Cutan Pathol* 1994;21:67-70.
15. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. *Oncology* 2000;58:185-90.
16. Dean JC. Prevention of doxorubicin-induced hair loss. *N Engl J Med* 1980;302:921.
17. Gates O. Cutaneous metastases of malignant disease. *Am J Cancer* 1937;30:718-30.
18. Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: a meta-analysis of data. *South Med J* 2003;96:164-7.
19. Spaeth D, Luporsi E, Weber B, et al. Efficacy and safety of cooling helmets (CH) for the prevention of chemotherapy-induced alopecia (CIA): A prospective study of 911 patients (pts). *J Clin Oncol* 2008;26.
20. Sande van de MAE, Hurk van den CJG, Breed WPM, Nortier JWR. Hoofdhuidmetastasen bij hoogrisico borstkankerpatienten. *Ned Tijdschr Geneesk* 2010;154:A2134.
21. Dean JC, Griffith S, Cetas TC, Mackel CL, Jones SE, Salmon SE. Scalp hypothermia: a comparison of ice packs and the kold kap in the prevention of doxorubicin-induced alopecia. *JCO* 1983;1:33-7.
22. Lemieux J, Amireault C, Provencher L, Maunsell E. Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. *Breast Cancer Res Treat* 2009;118:547-52.
23. Janssen FE. Modelling physiological and biochemical aspects of scalp cooling. Eindhoven: Technical University Eindhoven; MSc Thesis 2007.
24. Hurk van den CJG, Breed WPM, Mols F. Chemotherapy-induced hair loss. In: Preedy Ve, editor. *Handbook of Hair in Health and Disease*. Wageningen, The Netherlands: Wageningen Academic Publishers; 2012. p. 403-16.

25. Komen M, Smorenburg, CH, Breed, WPM, Van den Hurk, CJG, Nortier, JW. Evaluation of a trichometer to quantify the prevention of hair loss by scalp cooling during chemotherapy. Poster 546 ECCO Stockholm 2011.
26. Christodoulou C, Tsakalos G, Galani E, Skarlos DV. Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention. *Ann Oncol* 2006;17:350.
27. Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. *Cancer* 1984;54:34-7.
28. Lemieux J, Desbiens C, Hogue JC. Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up. *Breast Cancer Res Treat* 2011;128:563-6.
29. Breed WPM, Hurk van den CJG, Peerbooms M. Presentation, impact and prevention of chemotherapy-induced hair loss; scalp cooling potentials and limitations. *Exp Rev Dermatol* 2011;6:109-125.
30. Hurk van den CJG, Gerrits P, Graat J, Kolen B, Laar van de- Müskens J, Breed WPM. Positieve ervaringen met hoofdhuidkoeling in drie ziekenhuizen in Nederland. *Tijd voor een standaard aanbod van hoofdhuidkoeling?* *Oncologica* 2005;22:162-67 [article in Dutch].
31. Nakazawa M, Sakamoto T, Honda M, et al. Scalp hypothermia: a prevention of hair-loss in clinical oncology. *Dokkyo J Med Sci* 1985;12:17-24.
32. Keizer-Heldens P. Hoofdhuidkoeling bij haarverlies door chemotherapie. *Oncologica* 2009:29-34 [article in Dutch].
33. Kargar M, Sarvestani RS, Khojasteh HN, Heidari MT. Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy. *J Adv Nurs* 2011 epub ahead.
34. Hurk van den CJ, Mols F, Vingerhoets AJ, Breed WP. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. *Psych Oncol* 2010;19:701-9.
35. Hurk van den CJ, Breed WP, Nortier JW. Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. *Supp Care Cancer* 2012;20:3255-60.
36. Hurk van den CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. *Acta Oncol* 2012;51:497-504.
37. Hurk van den CJG, Akker van den -van Marle ME, Breed WPM, Poll van de-Franse LV, Nortier JWR, Coebergh JWW. Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer *J Oncol Nurse* (in press) 2013.
38. Mallon E, Dawber RP. Alopecia neoplastica without alopecia: a unique presentation of breast carcinoma scalp metastasis. *J Am Acad Dermatol* 1994;31:319-21.
39. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. *Cell* 2011;147:275-92.
40. Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. *Apmis* 2008;116:730-41.
41. Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW. Recurrence dynamics does not depend on the recurrence site. *Breast Cancer Res* 2008;10:R83.
42. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? *Nat Rev Cancer* 2010;10:871-7.
43. Moore S. Cutaneous metastatic breast cancer. *Clin J Oncol Nurs* 2002;6:255-60.
44. Toi M, Yamashiro H, Tsuji W. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. *Breast Cancer* 2009;16:207-18.
45. Kamby C. The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. *Cancer Treat Rev* 1990;17:37-61.